Skip to content
BiologicalX

Comparison

Alpha-Lipoic Acid vs Low-Dose Naltrexone

Side-by-side of Alpha-Lipoic Acid and Low-Dose Naltrexone. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Alpha-Lipoic Acid

  • Approved Rx for diabetic neuropathy in Germany at 600 mg/day IV (Thioctacid) since 1960s
  • Improves neuropathy symptoms (TSS, NIS) at 600 mg/day IV across ALADIN and SYDNEY trials
  • R-ALA enantiomer absorbs 40-100% better than racemic mixtures
  • Activates AMPK; produces small HbA1c reductions in T2DM
  • Plasma half-life ~30 minutes; split dosing or sustained-release is standard
  • Hypoglycemia risk with insulin or sulfonylureas; medication adjustment may be required

Low-Dose Naltrexone

  • Off-label use at 1.5 to 4.5 mg, roughly one-tenth the FDA-approved 50 mg addiction-treatment dose
  • Proposed mechanisms include brief opioid receptor blockade triggering rebound endogenous opioid release, plus TLR4 antagonism
  • Compounded prescription only; insurance rarely covers; cash prices 20 to 80 USD per month
  • Younger 2013 reported ~30% pain reduction in fibromyalgia at 4.5 mg in a small crossover trial
  • Smith 2011 reported endoscopic improvement in active Crohn's disease (n=40 placebo-controlled)
  • Vivid dreams affect 20 to 40% in first 2 weeks; manageable by switching to morning dosing

Side-by-side

Attribute Alpha-Lipoic Acid Low-Dose Naltrexone
Category supplement pharmaceutical
Also known as ALA, thioctic acid, R-ALA, R-lipoic acid LDN, naltrexone (low dose)
Half-life (hr) 0.5 4
Typical dose (mg) 600 4.5
Dosing frequency 1 to 3 times daily on empty stomach once daily, typically at bedtime
Routes oral, iv oral
Onset (hr) 0.5 1
Peak (hr) 1 1.5
Molecular weight 206.33 341.4
Molecular formula C8H14O2S2 C20H23NO4
Mechanism Dual lipid- and water-soluble antioxidant; redox cycles with dihydrolipoic acid (DHLA) to scavenge ROS, regenerate vitamin E and C, and chelate transition metals. Activates AMPK in liver and muscle; cofactor for pyruvate and alpha-ketoglutarate dehydrogenase complexes. Brief mu-opioid receptor antagonism proposed to trigger compensatory upregulation of endogenous opioids; secondary TLR4 antagonism on microglia and immune cells contributes to anti-inflammatory effect.
Legal status Dietary supplement (US, UK, Canada, most EU); prescription drug for diabetic neuropathy in Germany Off-label compounded prescription (naltrexone is FDA approved for opioid and alcohol use disorder at 50 mg)
WADA status allowed allowed
DEA / Rx Not scheduled Rx only (not a controlled substance)
Pregnancy Insufficient data; precautionary avoidance Insufficient data; not routinely recommended
CAS 62-46-4 16590-41-3
PubChem CID 864 5360515
Wikidata Q161227 Q426444

Safety profile

Alpha-Lipoic Acid

Common side effects

  • nausea
  • abdominal discomfort
  • diarrhea
  • sulfurous odor
  • rash (rare)

Contraindications

  • pregnancy and lactation (insufficient safety data)
  • active insulin autoimmune syndrome predisposition

Interactions

  • insulin and sulfonylureas: additive hypoglycemia; medication dose adjustment may be required(major)
  • thyroid hormone: may reduce T4 to T3 conversion at high doses(moderate)
  • biotin: ALA competes with biotin uptake; chronic use can induce biotin insufficiency(minor)
  • iron supplements: ALA chelates iron and reduces absorption; separate dosing(moderate)
  • chemotherapy (oxidative-stress-dependent agents): theoretical interference; coordinate with oncology team(moderate)

Low-Dose Naltrexone

Common side effects

  • vivid dreams
  • sleep disruption
  • headache
  • mild GI upset
  • fatigue (early)

Contraindications

  • concurrent opioid use
  • acute hepatitis or liver failure
  • opioid dependence
  • pregnancy (insufficient data)

Interactions

  • opioid analgesics (oxycodone, morphine, codeine): blocks analgesic effect; precipitates withdrawal in dependent users(major)
  • tramadol: blocks opioid component of analgesia(major)
  • thyroid hormone replacement: may alter dose requirements after immune modulation; monitor TSH(minor)

Which Should You Take?

Alpha-Lipoic Acid comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Low-Dose Naltrexone is the right call when one of the conditionals below applies.

Edge case: If you want to avoid prescription-only, Alpha-Lipoic Acid is the more accessible choice.

Default choice: Alpha-Lipoic Acid. Lower friction to source, and broader goal coverage. Reach for Low-Dose Naltrexone only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Alpha-Lipoic Acid and Low-Dose Naltrexone?

Alpha-Lipoic Acid and Low-Dose Naltrexone differ in category (supplement vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Alpha-Lipoic Acid or Low-Dose Naltrexone?

Alpha-Lipoic Acid half-life is 0.5 hours; Low-Dose Naltrexone half-life is 4 hours.

Can you stack Alpha-Lipoic Acid with Low-Dose Naltrexone?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper